<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220129</url>
  </required_header>
  <id_info>
    <org_study_id>2186</org_study_id>
    <nct_id>NCT00220129</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus</brief_title>
  <official_title>Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the efficacy and safety of epirubicin, cisplatin and&#xD;
      capecitabine (ECX) as neoadjuvant therapy prior to radical chemoradiotherapy using&#xD;
      capecitabine and cisplatin as radio-sensitisers in patients with newly diagnosed localized&#xD;
      squamous cell carcinoma of the oesophagus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective clinical response rate assessed by computed tomography (CT), endoscopic ultrasound (EUS) and endoscopic biopsy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients not achieving clinical complete response and requiring surgery after chemoradiation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of dysphagia</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Oesophageal Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Cisplatin, Capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Resection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Histologically verified squamous cell carcinoma of the cervical or thoracic oesophagus&#xD;
&#xD;
          -  American Joint Committee on Cancer (AJCC) Stage I-III (T1-3 N0-1 M0) (33), as assessed&#xD;
             by spiral or multi-slice computed tomography (CT) and endoscopic ultrasound, where&#xD;
             radical chemoradiation would be considered with curative intent.&#xD;
&#xD;
          -  No previous chemotherapy, radiotherapy or other investigational drug treatment for&#xD;
             this indication.&#xD;
&#xD;
          -  World Health Organization (WHO) performance status 0,1 or 2.&#xD;
&#xD;
          -  Adequate bone marrow function with platelets &gt; 100 x 10^9/l; white blood cells (WBC) &gt;&#xD;
             3 x 10^9/l; neutrophils &gt; 1.5 x 10^9/l at the time of study entry.&#xD;
&#xD;
          -  Serum bilirubin &lt; 35 micromol/l.&#xD;
&#xD;
          -  Serum creatinine &lt; 180 micromol/l and measured creatinine clearance over 60 ml/min.&#xD;
&#xD;
          -  No concurrent uncontrolled medical condition.&#xD;
&#xD;
          -  No previous malignant disease other than non-melanotic skin cancer or carcinoma in&#xD;
             situ of the uterine cervix in the last 10 years.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Adequate contraceptive precautions if relevant.&#xD;
&#xD;
          -  Informed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of locally advanced or metastatic disease precluding curative&#xD;
             chemoradiation (T4 or Stage IV or M1a-b) or disease not encompassable in a radical&#xD;
             radiotherapy field.&#xD;
&#xD;
          -  Total dysphagia (O'Rourke's swallowing function scoring system 5) precluding&#xD;
             swallowing of capecitabine even when crushed.&#xD;
&#xD;
          -  Medical or psychiatric conditions that compromise the patient's ability to give&#xD;
             informed consent.&#xD;
&#xD;
          -  Intracerebral metastases or meningeal carcinomatosis.&#xD;
&#xD;
          -  New York Heart Association classification Grade III or IV.&#xD;
&#xD;
          -  Uncontrolled angina pectoris.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Impaired renal function with measured creatinine clearance less than 60 ml/min.&#xD;
&#xD;
          -  Previous investigational study drug&#xD;
&#xD;
          -  Known malabsorption syndromes&#xD;
&#xD;
          -  Patients with a known hypersensitivity to fluorouracil (5-FU) or with a&#xD;
             dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  Hearing loss&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 15, 2009</last_update_submitted>
  <last_update_submitted_qc>December 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jane Lawrence</name_title>
    <organization>Royal Marsden NHS Foundation Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

